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The risk of atherosclerosis is inversely associ-
ated with plasma levels of high-density lipopro-
tein cholesterol (HDL-C). However, HDL metab-
olism is incompletely understood, and there are
few effective approaches to modulate HDL-C
levels. Here we show that inhibition in the liver
of the classical proprotein convertases (PCs),
but not the atypical PCs S1P and PCSK9, de-
creases plasma HDL-C levels. This metabolic
effect of hepatic PCs is critically dependent on
expression of endothelial lipase (EL), an en-
zyme that directly hydrolyzes HDL phospho-
lipids and promotes its catabolism. Hepatic
PCs reduce EL function through direct inacti-
vating cleavage of EL aswell as through activat-
ing cleavage of angiopoietin-like protein 3
(ANGPTL3), an endogenous inhibitor of EL.
Thus, inhibition of hepatic PCs results in in-
creased EL activity, leading to reduced HDL-C
as well as impaired reverse cholesterol trans-
port. The hepatic PC–ANGPTL3–EL–HDL path-
way is therefore a novel mechanism controlling
HDL metabolism and cholesterol homeostasis.
INTRODUCTION
Proprotein convertases (PCs) belong to a family of subtil-
isin-related serine endopeptidases that is conserved from
bacteria to mammals. This subfamily comprises nine
members: furin, PCSK1, PCSK2, PCSK4, PACE4, PCSK5,
S1P, PCSK7, and PCSK9. The physiological role of the
individual PCs in mammals has recently been directly ex-
amined through genetic manipulation. The prototype furin
and two closely related PCs, PCSK5 and PACE4, are
essential for normal embryonic development; inactivation
of any of genes that encode these proteins causes embry-
onic death in mice at various stages (Scamuffa et al.,
2006). However, their postnatal physiological roles are still
unknown.CellClassically, the PCs are known to proteolytically acti-
vate peptides/proproteins by cleavage at paired basic
amino acid sites. The recognition sequence is relatively
nonspecific, with the general formula (R/K)-Xn-(R/K),
where n = 0, 2, 4, or 6 (Seidah and Chretien, 1999). In
this regard, PCSK9 and S1P are atypical PCs that cleave
at nonbasic sites. Not surprisingly, the list of substrates
of PCs has grown, and speculated physiological roles of
PCs have broadened to include homeostasis as well as
pathological states such as neurodegenerative disease,
pathogen invasion, and cancer (Basak, 2005). However,
most of the classical PC substrates have not yet been
demonstrated in vivo.
Moreover, PCs are considered to be redundant, as early
in vitro work showed that several PCs can cleave the same
substrates and that they are often coexpressed in the
same cell type (Seidah and Chretien, 1999). Consistent
with this concept, upon hepatic inactivation of furin, the
processing of the insulin receptor was normal, and only
mild effects of reduced cleavage were observed for the
substrates albumin, a5 integrin, lipoprotein receptor-
related protein, vitronectin, and a1-microglobulin/bikunin.
None of the tested substrates displayed a complete block
in processing (Roebroek et al., 2004). Thus, understanding
the physiological role of PCs may require inhibition of all of
the closely related PCs expressed in a particular cell type.
S1P and PCSK9 have been shown to modulate choles-
terol metabolism. S1P, an endoplasmic reticulum-local-
ized PC that cleaves membrane-bound sterol regulatory
element-binding proteins (SREBPs) at an RSVL site, is
required to release the active form of SREBPs to maintain
cellular cholesterol homeostasis (Goldstein et al., 2002).
PCSK9, after autocleavage at a VFAQ site, promotes
degradation of low-density lipoprotein receptor (LDLR)
through an unknown mechanism, a pathway supported
by genetic data from humans (Abifadel et al., 2003; Cohen
et al., 2005) as well as in vivo studies in mice (Benjannet
et al., 2004; Maxwell and Breslow, 2004; Park et al., 2004).
However, whether the classical PCs are also involved in
lipid homeostasis is unknown.
Both loss-of-function and overexpression studies have
established that the lipolytic enzyme endothelial lipase
(EL) is a negative regulator of plasma high-density lipopro-
tein (HDL) levels (Ishida et al., 2003; Jaye et al., 1999; JinMetabolism 6, 129–136, August 2007 ª2007 Elsevier Inc. 129
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is cleaved by members of the PC family including furin,
PACE4, and PCSK5A and that cleavage of EL resulted in
its inactivation in vitro (Jin et al., 2005). Because these
classical PCs are ubiquitously expressed, it was unclear
whether their tissue-specific expression has any effects
on EL cleavage in vivo and, as such, controls EL activity
and HDL levels. Here, we provide evidence that hepatic
PCs are able to modify EL activity both directly and indi-
rectly and thus influence HDL metabolism and reverse
cholesterol transport in mice.
RESULTS AND DISCUSSION
Inhibition of Hepatic PCs Decreases HDL
Cholesterol Levels
The prosegment of human furin (profurin) was used to in-
hibit classical PCs in vivo for several reasons. Purified full-
length profurin has been reported to be a potent inhibitor
of furin and PCSK5, and to a lesser extent PCSK7 and
PACE4, in a cell-free system (Zhong et al., 1999), and pro-
furin is effective in inhibiting the processing of various cel-
lular precursors including proNGF, proBDNF (Zhong et al.,
1999), proVEGF-C (Nour et al., 2003), and proBACE1
(Benjannet et al., 2001) in vitro. In addition, profurin is an
intracellular inhibitor of some classical PCs including furin,
PCSK5, and PACE4 (see Figure S1 in the Supplemental
Data available with this article online), but autocatalytic
cleavage of PCSK9 and S1P was not altered by profurin
overexpression (Figure S2). To confirm that profurin can
inhibit murine PCs in liver, primary murine hepatocytes
were isolated 3 days after in vivo infection with either ad-
enovirus encoding human profurin and an internal ribo-
somal entry site-linked EGFP reporter gene (Ad-profurin)
or control adenovirus containing no transgenic expression
cassette (Ad-null). The transduction efficiency was 90%
by fluorescence-activated cell sorting analysis of en-
hanced green fluorescent protein (EGFP) expression (data
not shown). The expression of human profurin protein was
confirmed by western blotting (Figure 1A) using an anti-
body specific for human profurin (Zhong et al., 1999). PC
activity was measured in the conditioned medium. In the
presence of profurin overexpression, secreted PC activity
was approximately 50% of that of the control (Figure S3).
All of the PC activity detected in the conditioned medium
was inhibited by another PC-specific inhibitor, a1-PDX
(Watanabe et al., 1995), indicating that overexpression
of profurin only partially inhibits hepatic PC activity (data
not shown). Plasma alanine aminotransferase levels were
not altered after overexpression of profurin (data not
shown), and morphologic assessment of mouse livers by
hematoxylin and eosin staining did not reveal any gross
changes, indicating that partial PC inhibition does not
cause damage to hepatocytes (Figure S4).
When profurin was overexpressed in mice, plasma HDL
cholesterol (HDL-C) and phospholipids were significantly
reduced at day 3 compared to those in the Ad-null-
injected mice and returned to baseline by day 14 (Figures
1B and 1C). However, glucose and free fatty acids were130 Cell Metabolism 6, 129–136, August 2007 ª2007 Elsevier Innot altered (data not shown). The plasma lipid profiles on
day 3 after injection were further examined by fast protein
liquid chromatography (FPLC) analysis, and the HDL-C
levels were found to be reduced (Figure S5). Agarose gel
electrophoresis was also used to separate lipoproteins
based upon their charge. a-migrating lipoproteins (HDL)
and b-migrating lipoproteins (LDL) were decreased in the
Ad-profurin-treated mice, with no increase in pre-b-
migrating lipoproteins (very low-density lipoprotein and
pre-b HDL) (Figure S6). The protein composition in the
HDL fractions was analyzed, and apoA-I, apoA-II, apoE,
apoC-I, and apoC-III were all significantly reduced (Table
S1). The reduced apoA-II and apoE proteins in HDL frac-
tions were confirmed by immunoblotting (Figures S7A
and S7B). Profurin expression had no effect on the secre-
tion of apoA-I from primary murine hepatocytes (Fig-
ure S7C). In Ad-profurin-treated plasma, the mature form
of apoA-I was barely detectable, but pro-apoA-I was com-
parable to that seen in control plasma (Figure S7D). No
Figure 1. Profurin and Plasma Lipid Levels after Inhibition of
Hepatic Proprotein Convertases in Wild-Type Mice
A single dose of Ad-null or Ad-profurin was injected in wild-type mice.
(A) Western blotting of profurin protein expression in vivo after trans-
duction. Similar amounts of proteins from liver lysates (10 mg/lane)
were loaded.
(B and C) Blood was sampled at the indicated time points, and plasma
lipid profile for high-density lipoprotein cholesterol (HDL-C) (B) and
phospholipids (C) was determined as described in Experimental
Procedures.
nR 4 mice per group; *p < 0.05, **p < 0.01. Each experiment was re-
peated 12 times. In this and all other figures, error bars represent ± SD.c.
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known to influence HDL levels (Acton et al., 1996; Christi-
ansen-Weber et al., 2000; Rader, 2006), were observed in
the mice overexpressing profurin (Figure S8).
EL-Dependent Effects of Inhibition of Hepatic
PCs on HDL Metabolism
We hypothesized that hepatic PC-mediated cleavage and
inactivation of EL influences HDL metabolism and that in-
hibition of hepatic PCs reduces HDL-C by increasing EL
activity. To test whether EL is a substrate of hepatic PCs
in vivo, the EL protein was analyzed in plasma from either
Ad-null- or Ad-profurin-treated mice. To separate the full-
length EL from albumin, two-dimensional electrophoresis
was performed, and EL protein was detected by using
a polyclonal antibody to mouse EL. As shown in Figure 2A,
inhibition of hepatic PCs reduced generation of the 40 kDa
cleavage product and increased the full-length 68 kDa
form of EL in the Ad-profurin-treated plasma. Neither of
these two forms of EL protein was detected in plasma
from EL knockout mice (data not shown).
To test whether inhibition of hepatic PCs increases
plasma phospholipase activity, this parameter was mea-
sured in mouse postheparin plasma, where it was found
to be increased 2.3-fold in Ad-profurin-treated plasma
compared to control plasma (p < 0.01, Figure 2B). To ex-
amine whether inhibition of hepatic PCs increases HDL-
phospholipid catabolism, HDL from wild-type mice was
labeled with [14C]phosphatidylcholine and injected into
mice that had been infected with Ad-null or Ad-profurin
3 days earlier. The clearance of HDL-PC was significantly
increased in the Ad-profurin-treated mice (Figure 2C). The
fractional catabolic rates were 1.67 ± 0.49 versus 4.32 ±
0.93 pool/hr (p < 0.01) for control- and profurin-treated
mice, respectively. This rapid catabolism of HDL particles
may explain the increased ratio of pro-apoA-I to mature
apoA-I seen in ABCA1-deficient patients (Bojanovski
et al., 1987). Thus, increased catabolism of HDL due to
increased EL activity is likely the mechanism by which
inhibition of hepatic PCs decreases HDL levels.
To prove that endogenous EL expression is required for
the lipid phenotype observed after hepatic PC inhibition,
Ad-profurin was injected into EL knockout mice. In con-
trast to wild-type mice, HDL levels were not changed after
hepatic PC inhibition in these mice (Figure 2D). The frac-
tional catabolic rates of HDL were not significantly differ-
ent between control- and profurin-treated EL knockout
mice (1.03 ± 0.16 versus 1.28 ± 0.34 pool/hr, respectively)
(Figure 2E). To exclude the in vivo effects of another phos-
pholipase in the same family as EL, hepatic lipase (HL)
(Wong and Schotz, 2002), which is not cleaved by PCs
(data not shown), a similar experiment was performed in
HL knockout mice. HDL levels were markedly reduced
and virtually undetectable at day 3 after Ad-profurin ad-
ministration in these mice (Figure 2F). Therefore, regula-
tion of HDL levels by hepatic PCs is dependent on the
expression of endogenous EL, but not HL.
To test whether increased hepatic PC expression would
lead to an elevation of HDL levels, PCSK5A, a representa-Celltive classical PC, was overexpressed in wild-type mice.
Overexpression of PCSK5A resulted in a significant in-
crease of HDL-C levels, with a peak increase of 50%
(Figure 2G). Both total cholesterol and phospholipid levels
were also increased in parallel (data not shown). The
change in HDL levels was similar to that in EL knockout
mice as reported by Ishida et al. (2003) and Ma et al.
(2003). Consistently, plasma EL cleavage products were
increased after PCSK5A overexpression (Figure S9). To
determine whether the effects of PCSK5A overexpression
are dependent on EL, a similar experiment was performed
in EL knockout mice. As expected, HDL-C levels were not
different between the PCSK5A-expressing group and
control group (Figure 2H), confirming that the ability of
PCSK5A overexpression to raise HDL is dependent on
endogenous EL.
Inhibition of Hepatic PCs Decreases the Cleavage
of Angiopoietin-like Protein 3
Angiopoietin-like protein 3 (ANGPTL3), a liver-derived
member of the vascular endothelial growth factor family,
has been shown to be an inhibitor of LPL (Shimizugawa
et al., 2002) and EL (Shimamura et al., 2007) in cell-free
systems and has been suggested to play a potential role
in regulating HDL levels (Koishi et al., 2002). To test
whether ANGPTL3 inhibits EL in vitro, a plasmid express-
ing murine ANGPTL3 was transfected into HEK293 cells
stably expressing EL. ANGPTL3 inhibited 60% of EL ac-
tivity without affecting the amount of EL mass in the con-
ditioned medium (Figure 3A) but did not inhibit HL activity
(Figure S10). Interestingly, murine ANGPTL3 has been
shown to be cleaved in vitro and in vivo at a classical PC
recognition sequence, RAPR224 (Ono et al., 2003). The
cleavage of murine ANGPTL3 was totally blocked in
HEK293 cells stably expressing profurin (Figure 3B). The
importance of the cleavage of ANGPTL3 for EL activity
was further examined by comparing the inhibitory effects
of the full-length ANGPTL3 on EL activity to the effects of
the cleavage-product N terminus of ANGPTL3. As shown
in Figure 3C, the N terminus of ANGPTL3 inhibited EL
activity more effectively than the uncleavable ANGPTL3
did (p < 0.05). Thus, cleavage of ANGPTL3 is an activation
process releasing the active form of ANGPTL3 (N termi-
nus), which is more effective at inhibiting EL.
To test whether hepatic PC inhibition decreased the
cleavage of ANGPTL3 in vivo, we examined endogenous
ANGPTL3 in plasma by western blotting. Profurin dramat-
ically reduced ANGPTL3 cleavage in mice (Figure 3D, up-
per panel). After mouse plasma was separated by FPLC,
the C-terminal ANGPTL3 protein was detected in lipid-
poor fractions and was not associated with HDL fractions.
Importantly, fewer cleavage products of ANGPTL3 were
generated in mice treated with Ad-profurin compared to
the control (Figure 3D, lower panel). When primary hepa-
tocytes were isolated after infection, Ad-profurin-trans-
duced hepatocytes produced significantly less of the
cleavage products, with an increase in the full-length
ANGPTL3 (data not shown). Thus, ANGPTL3 is an authen-
tic hepatic PC substrate in vivo. Inhibition of PC cleavageMetabolism 6, 129–136, August 2007 ª2007 Elsevier Inc. 131
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(A) Effects of inhibition of hepatic proprotein convertases (PCs) on the cleavage of endothelial lipase (EL) in mice. Ten microliters of plasma was
separated by two-dimensional electrophoresis, and EL protein was detected by western blotting. F: full-length protein (dotted box); N: cleaved
N-terminal fragment (oval).
(B) Effects of inhibition of hepatic PCs on postheparin plasma phospholipase activity. n = 4; *p < 0.05.
(C) Effects of inhibition of hepatic PCs on HDL-phospholipid catabolism in wild-type (WT) mice. n = 4; p < 0.01.
(D) Effects of inhibition of hepatic PCs on HDL levels in EL knockout mice (top) and western blotting of profurin in liver lysates after transduction
(bottom).
(E) Effects of inhibition of hepatic PCs on HDL-phospholipid catabolism in EL knockout mice. n = 4; p < 0.01.
(F) Effects of inhibition of hepatic PCs on HDL levels in HL knockout mice (top) and western blotting of profurin in liver lysates after transduction
(bottom).
(G and H) Effects of PCSK5A on HDL levels in wild-type (G) and EL knockout mice (H).
nR 4 mice per group; *p < 0.05.132 Cell Metabolism 6, 129–136, August 2007 ª2007 Elsevier Inc.
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(A) ANGPTL3 inhibited EL activity in vitro.
(B) Profurin prevented the cleavage of ANGPTL3 in vitro.
(C) The N terminus of ANGPTL3 (R221X) was a more potent inhibitor of EL than uncleavable ANGPTL3 (R224A). Data are expressed as percent of the
control. n = 3; *p < 0.05.
(D) Effects of inhibition of hepatic PCs on the cleavage of ANGPTL3 in mice. Upper panel: plasma (0.1 ml/lane); lower panel: FPLC fractions 39–41,
which elute later than HDL. F: full-length protein; C: cleaved C-terminal fragment.reduced activation of ANGPTL3, leading to reduced inhi-
bition of EL by ANGPTL3 (Figure 3C). This likely contrib-
utes to the decreased HDL levels seen in profurin-treated
mice.
Inhibition of Hepatic PCs Decreases Reverse
Cholesterol Transport
Because a major atheroprotective mechanism of HDL is
the promotion of cellular efflux of cholesterol from macro-
phages, we addressed whether reduced HDL levels in the
Ad-profurin-treated serum are associated with reduced
macrophage cholesterol efflux and reverse cholesterol
transport (RCT). The ability of serum from mice injected
with either Ad-null or Ad-profurin to mediate cholesterol
efflux was assessed in vitro (Yancey et al., 2004). The
ABCA1-mediated efflux was abolished and the efflux via
SR-BI was decreased by 93% using serum from Ad-pro-
furin-treated mice (Figures 4A and 4B). To examine the ef-
fect of hepatic PC inhibition on macrophage RCT in vivo
(Zhang et al., 2003), [3H]cholesterol-labeled, cholesterol-
loaded J774 cells were injected intraperitoneally intoCellmice 3 days after the mice were transduced with either
Ad-null or Ad-profurin. The Ad-profurin-treated mice had
significantly lower plasma [3H]cholesterol levels at all time
points studied: 64% (p < 0.01) lower at 2 hr, 71% (p < 0.01)
lower at 6 hr, 72% (p < 0.01) lower at 24 hr, and 73%
(p < 0.01) lower at 48 hr (Figure 4C). The level of tracer in
the livers of Ad-profurin-treated mice was 37% lower
(Figure 4D, p < 0.05). The [3H]bile acids in the Ad-profurin-
treated mice were also significantly (41%, p < 0.05) lower
compared to controls (Figure 4E). Consistently, the Ad-
profurin-treated mice excreted 59% less tracer in feces
(p < 0.05) over 48 hr than control mice (Figure 4F). We
observed similar results when EL was overexpressed in
wild-type mice (data not shown).
Our studies demonstrate that hepatic PCs play a physi-
ological role in HDL metabolism in vivo and that both EL
and ANGPTL3 are physiological substrates of hepatic
PCs mediating the effects on HDL through two pathways.
Hepatic PCs regulate EL function through cleavage of EL,
a direct inactivation of EL lipolytic activity, and cleavage of
ANGPTL3, an indirect process of activation of an inhibitorMetabolism 6, 129–136, August 2007 ª2007 Elsevier Inc. 133
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PCs on Reverse Cholesterol Transport
(A) The measurement of ABCA1-specific efflux
to mouse plasma in J774 cells. Data in (A) and
(B) are expressed as percent of the control.
n = 3; *p < 0.05.
(B) The measurement of SR-BI-specific efflux
to mouse plasma in Fu5AH cells.
(C–F) Mice were injected intraperitoneally with
ac-LDL-loaded J774 macrophages labeled
with [3H]cholesterol. The percent of macro-
phage-derived [3H]cholesterol appearing in
plasma (C), liver at 48 hr (D), bile at 48 hr (E),
and feces over 48 hr (F) after macrophage
injection is shown. Data are expressed as
percent of the initial amount of [3H]cholesterol
injected intraperitoneally. n = 6; *p < 0.05.of EL. Thus, inhibition of hepatic PCs increases EL activity,
resulting in a reduction of plasma HDL levels (Figure S11).
The relative contribution of these two pathways is un-
known, and further work will be required to determine
the overall importance of each component of the system.
The physiological significance of hepatic PCs is further
supported by the fact that inhibition of hepatic PCs re-
duces RCT. In parallel to the known role of S1P and PCSK9
in regulating LDL metabolism through the LDLR, the
PC–ANGPTL3–EL–HDL pathway is a critical mechanism
for fine tuning HDL metabolism. This proteolytic cascade
opens a new avenue in the proprotein convertase field and
suggests several novel targets for raising HDL-C levels
and promoting RCT. More experiments to determine
which endogenous proprotein convertases are most rele-
vant in regulation of HDL metabolism and to demonstrate
that there is physiological regulation of this system are
warranted. Insights gained from these studies could lead
to new ways to therapeutically regulate HDL levels.
Our current studies indicate the physiological impor-
tance of EL, whose function is normally suppressed by he-
patic PCs and ANPTL3. Importantly, this PC–ANGPTL3–
EL system has a large capacity to modulate HDL levels.
It is conceivable that this mechanism could be altered and
could contribute to the changes of HDL metabolism under
pathophysiological or disease conditions, a possibility that
is currently under investigation. Furthermore, these stud-
ies provide an example of how the liver regulates HDL
catabolism through an irreversible proteolytic cascade.134 Cell Metabolism 6, 129–136, August 2007 ª2007 ElsevierThis model may apply to other proteolytic events in lipid
and lipoprotein metabolism as well.
EXPERIMENTAL PROCEDURES
Construction of Adenoviral Vectors
Recombinant, replication-defective adenoviruses encoding human
profurin, murine pcsk5a, or murine angptl3 were generated by the
Vector Core at the University of Pennsylvania. To better trace the ex-
pression of human profurin in vivo, an adenovirus encoding the human
profurin cDNA and an internal ribosomal entry site-linked EGFP
reporter gene, both driven by the CMV promoter, was generated.
The control adenovirus, Ad-null, contained no transgenic expression
cassette.
Western Blotting
SDS-PAGE and immunoblot analysis were carried out as previously
described (Jin et al., 2005). The primary antibody used was a rabbit
polyclonal antibody against murine EL (Jin et al., 2003). A rabbit poly-
clonal antibody to murine ANGPTL3 was generated according to the
method previously described (Jin et al., 2003). FPLC fractions 39–41
were used for the detection of ANGPTL3. For two-dimensional gel
electrophoresis, plasma samples were pipetted into the bottom of a
protein isoelectric focusing (IEF) apparatus (GE Healthcare/Amer-
sham) and were focused onto a freshly thawed Immobiline DryStrip
(GE Healthcare/Amersham) after stepwise voltage increases to a total
of 71,500 volt hours. After IEF, the proteins were subjected to second-
dimension separation according to their size.
Animal/Plasma Analysis
Female 8-week-old C57BL/6 mice obtained from Taconic and 8-week-
old EL knockout mice were used for the experiments. All mice were fed
a chow diet. For blood sampling, mice were fasted for 4 hr and bledInc.
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ministered via tail vein on day 0 of the study. Blood samples were taken
at the days indicated after virus injection. Plasma lipids were measured
using previously reported methods, and FPLC analysis was performed
on pooled samples (Jin et al., 2003). The University of Pennsylvania
Institutional Animal Care and Usage Committee approved the experi-
ments, and all procedures were performed as recommended by the
NIH Guide for the Care and Use of Laboratory Animals and the Labo-
ratory Animal Welfare Act.
Lipase Activity Assays
EL-specific and HL-specific triglyceride lipase and postheparin plasma
phospholipase activities were assayed as previously described (Jin
et al., 2005).
PC Activity Assays
PC activity assay was performed using the fluorogenic peptide Pyr-
RVRR-AMC (Bachem) as the substrate. One unit is defined as the
amount of furin that will release 1 pmol of AMC from the fluorogenic
peptide Pyr-RVRR-AMC in a total reaction volume of 100 ml in 1 min
(1 pmol of AMC/min) at 37C in 100 mM HEPES (pH 7.5 at 25C)
with 0.5% Triton X-100, 1 mM CaCl2, 1 mM 2-mercaptoethanol, and
100 mM Pyr-RVRR-AMC.
Histology
Animals were sacrificed and livers were fixed with 4% paraformalde-
hyde at 4C. Paraffin sections (4 mm) were stained with hematoxylin
and eosin and were examined and photographed with a Nikon Eclipse
E-800 microscope.
Native Gel Electrophoresis
Lipoproteins were separated by agarose gel electrophoresis using
Titan gels (Helena) according to the manufacturer’s standard protocol.
Proteomics
Proteins in the HDL fraction were extracted with methanol/chloroform
and analyzed as previously described (Sewell et al., 2006). All data
were normalized to volume. This experiment was repeated eight times.
Primary Hepatocyte Culture
C57BL/6J mice were injected with the indicated adenovirus, and 3
days later, primary hepatocytes were isolated as previously described
(Park et al., 2004). The hepatocytes were allowed to attach on type I
collagen-coated six-well plates for 4 hr in DMEM. The cells were
then incubated with serum-free DMEM for another 24 hr.
HDL Turnover Experiments
Wild-type mice were infected with either Ad-null or Ad-profurin 3 days
before the turnover study. Mouse HDL was isolated from wild-type
mice and labeled with [14C]phosphatidylcholine, and kinetic studies
were performed as previously described (Jin et al., 2003). The frac-
tional catabolic rates of HDL phospholipid were calculated with the
WinSAAM program by fitting a biexponential curve to the plasma
counts normalized to the 1 min time point.
Plasmids and Cell Culture
Constructs expressing uncleavable ANGPTL3 (R224A) and the N ter-
minus of ANGPTL3 (R221X), each with a C-terminal Myc-His tag, were
generated. Conditioned media containing R224A or R221X were gen-
erated and quantitated using a modified ELISA with anti-Myc antibody.
Equal amounts of R224A or R221X protein were used to incubate cells
stably expressing EL for 24 hr.
Measurement of Cholesterol Efflux In Vitro and RCT In Vivo
SR-BI-mediated cholesterol efflux and ABCA1-mediated free choles-
terol efflux was measured as previously described (Yancey et al.,
2004). In vivo RCT was performed as previously described (Zhang
et al., 2003).Cell MStatistics
Data are presented as means ± SD. Multiple (>2) group study data
were subjected to two-way analysis of variance (ANOVA) and the New-
man-Keuls multiple comparison test. Two-tailed Student’s t tests were
used for the mean of two groups, and statistical significance for all
comparisons was assigned at p < 0.05. All calculations were per-
formed using GraphPad Prism version 4.03 (GraphPad Software).
Supplemental Data
Supplemental Data include eleven figures and one table and can be
found with this article online at http://www.cellmetabolism.org/cgi/
content/full/6/2/129/DC1/.
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